Abstract
Neuropsychiatric (NP) syndromes in rheumatic disorders in the elderly represent a field of medicine situated at the crossroads of neurology, psychiatry, rheumatology, immunology, and geriatrics. NP symptoms highly prevalent in rheumatic conditions, are a major source of disability and diminished quality of life, and potentially represent the target of treatment interventions that stand to significantly decrease the suffering they generate. The NP manifestations in rheumatic diseases in the elderly may be focal or generalized or a secondary consequence of the primary disease. A focal cerebral event may result in (1) a stroke-like presentation with an acute neurologic deficit, (2) a headache due to hemorrhage (e.g., subarachnoid hemorrhage in vasculitis) or temporal arteritis, (3) focal seizures, (4) optic neuropathy or cranial neuropathies due to compression by granulomatous lesions. A generalized event may result in cognitive dysfunction, headaches, or seizures. The spinal cord may be involved with resulting paraparesis, bowel or bladder dysfunction, or sensory disturbances. A common peripheral nervous system involvement is peripheral neuropathy, with symptoms of numbness, sensory paresthesias, weakness, or gait imbalance; nevertheless neuropathy may be multifocal and asymmetric. The presence of comorbid conditions and treatment adverse events including infections associated with immunosuppressive treatment or biologic therapy may compound the sign and symptoms of the NP syndromes of the underlying disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Fulop Jr T, Larbi A, Dupuis G, Pawelec G. Aging, autoimmunity and arthritis: Perturbations of TCR signal transduction pathways with ageing—a biochemical paradigm for the aging immune system. Arthritis Res Ther. 2003;5:290–302.
Godbout JP, Johnson RW. Age and neuroinflammation: a lifetime of psychoneuroimmune consequences. Neurol Clin. 2006;24:521–38.
Stichel CC, Luebbert H. Inflammatory processes in the aging mouse brain: participation of dendritic cells and T-cells. Neurobiol Aging. 2007;28:1507–21.
Rovensky J, Tuchynova A. Systemic lupus erythematosus in the elderly. Autoimmun Rev. 2008;7:235–9.
Lazaro D. Elderly-onset systemic lupus erythematosus: prevalence, clinical course and treatment. Drugs Aging. 2007;24:701–15.
Bertoli AM, Alarcón GS, Calvo-Alen J, Fernandez M, Vila LM, Reveille JD. LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US cohort. XXXIII. Clinical [corrected] features, course, and outcome in patients with late-onset disease. Arthritis Rheum. 2006;54:1580–7.
Ward MM, Polisson RP. A meta-analysis of the clinical manifestations of older-onset systemic lupus erythematosus. Arthritis Rheum. 1989;32:1226–32.
Costallat LT, Coimbra AM. Systemic lupus erythematosus: clinical and laboratory aspects related to age at disease onset. Clin ExpRheumatol. 1994;12:603–7.
Ho CT, Mok CC, Lau CS, Wong RW. Late onset systemic lupus erythematosus in southern Chinese. Ann Rheum Dis. 1998;57: 437–40.
Antolin J, Amerigo MJ, Cantabrana A, Roces A, Jimenez P. Systemic lupus erythematosus: clinical manifestations and immunological parameters in 194 patients: subgroup classification of SLE. Clin Rheumatol. 1995;14:678–85.
Ballok DA. Neuroimmunopathology in a murine model of neuropsychiatric lupus. Brain Res Rev. 2007;54:67–79.
Scolding NJ, Joseph FG. The neuropathology and pathogenesis of systemic lupus erythematosus. Neuropathol Appl Neurobiol. 2002;28:173–89.
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999; 42:599–608.
Ardilla A. Normal aging increases cognitive heterogeneity: analysis of dispersion in WAIS-III scores across age. Arch Clin Neuropsychol. 2007;22:1003–11.
Quemeneur T, Lambert M, Hachulla E, Dubucquoi S, Caron C, Fauchais AL, et al. Significance of persistent antiphospholipid antibodies in the elderly. J Rheumatol. 2006;33:1559–62.
Bonfa E, Golombek SJ, Kaufman LD, Skelly S, Weissbach H, Brot N, et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med. 1987;317:265–71.
Isshi K, Hirohata S. Association of anti-ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 1996;39:1483–90.
Conti F, Alessandri C, Bompane D, Bombardieri M, Spinelli FR, Rusconi AC, et al. Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: a role for anti-endothelial-cell antibodies. Arthritis Res Ther. 2004;6:R366–72.
Gerli R, Caponi L, Tincani A, Scorza R, Sabbadini MG, Danieli MG, et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford). 2002;41:1357–66.
Sullivan EV, Pfefferbaum A. Neuroradiological characterization of normal adult ageing. Br J Radiol. 2007;80:S99–108.
Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222–33.
Levin SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, Sciacca RL, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291:576–84.
Hereng T, Lambert M, Hachulla E, Samor M, Dubucquoi S, Caron C, et al. Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients. Lupus. 2008;17: 11–5.
Carsons S, Talal N. Sjögren’s syndrome in the 21st century. Intl J Adv Rheumatol. 2003;1:139–47.
Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren’s syndrome. Arch Intern Med. 2004;164: 1275–84.
Ng KP, Isenberg DA. Sjögren’s syndrome: diagnosis and therapeutic challenges in the elderly. Drugs Aging. 2008;25:19–33.
Tzioufas AG, Voulgarelis M. Update on Sjögren’s syndrome autoimmune epithelitis: from classification to increased neoplasia. Best Pract Res Clin Rheumatol. 2007;21:989–1010.
Attwood W, Poser CM. Neurologic complications of Sjögren’s syndrome. Neurology. 1961;11:1034–41.
Goransson LG, Herigstad A, Tjensvoll AB, Harboe E, Mellgren SI, Omdal R. Peripheral neuropathy in primary Sjögren’s syndrome: a population-based study. Arch Neurol. 2006;63:1612–5.
Andonopoulos AP, Lagos G, Drosos AA, Moutsopoulos HM. The spectrum of neurological involvement in Sjögren’s syndrome. Br J Rheumatol. 1990;29:21–3.
Delalande S, de Seze J, Fauchais AL, Hachulla E, Stojkovic T, Ferriby D, et al. Neurologic manifestations in primary Sjögren’s syndrome: a study of 82 patients. Medicine (Baltimore). 2004;83: 280–91.
Valtysdottir ST, Gudbjornsson B, Lindqvist U, Hallgren R, Hetta J. Anxiety and depression in patients with primary Sjögren’s syndrome. J Rheumatol. 2000;27:165–9.
Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. European Study Group on classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554.
Morgen K, McFarland HF, Pillemer SR. Central nervous system disease in primary Sjögren’s syndrome: the role of magnetic resonance imaging. Semin Arthritis Rheum. 2004;34:623–30. Review.
Shirota Y, Illei GG, Nikolov NP. Biologic treatments for systemic rheumatic diseases. Oral Dis. 2008;14:206–16.
Moore PM, Cupps TR. Neurological complications of vasculitis. Ann Neurol. 1983;14(2):155–67.
Nadeau SE. Neurologic manifestations of systemic vasculitis. Neurol Clin. 2002;20:123–50. Review.
Hunder GG. Giant cell arteritis and polymyalgia rheumatica. Med Clin North Am. 1997;811:195–219.
Walker RA, Wadman MC. Headache in the elderly. Clin Geriatr Med. 2007;23:291–305.
Nesher G. Neurologic manifestations of giant cell arteritis. Clin Exp Rheumatol. 2000;18:S24–6.
Pfadenhauer K, Roesler A, Golling A. The involvement of the peripheral nervous system in biopsy proven active giant cell arteritis. J Neurol. 2007;254:751–5.
Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 2004;50:1332–7.
Jennette J, Falk R, Andrassy K, et al. Nomenaclature of systemic vasculitis. Proposed of an international consensus conference. Arthritis Rheum. 1994;37:187–92.
Tervaert JWC, Kallenberg C. Neurologic manifestations of systemic vasculitides. Rheum Dis Clin North Am. 1993;19: 913–40.
Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsles W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and Polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66:222–7.
Cattaneo L, Chierici E. pavone L, Grasselli C, Manganelli P, Buzio C, Pavesi G. Peripheral neuropathy in Wegener’s granulomatosis, Churg-Strauss syndrome and microscopic polyangiitis. J Neurol Neurosurg Psychiatry. 2007;78:1119–23.
de Groot K, Schmidt DK, Arlt AC, Gross WL, Reinhold-keller E. Standardized neurologic evaluations of 128 patients with Wegener granulomatosis. Arch Neurol. 2001;58:1215–21.
Lie JT. Primary (granulomatous) angiitis of the central nervous system: a clinicopathologic analysis of 15 new cases ands a review of literature. Hum Pathol. 1992;23:164–71.
Chang DJ, Paget SA. Neurologic complications of rheumatoid arthritis. Rheum Dis Clin North Am. 1993;19:955–73. Review.
Kato T, Hoshi K, Sekijima Y, Mastuda M, Hashimoto T, Otani M, et al. Rheumatoid meningitis: an autopsy report and review of the literature. Clin Rheumatol. 2003;22:475–80.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Mikdashi, J.A. (2011). Neuropsychiatric Manifestations of Rheumatic Diseases in the Elderly. In: Nakasato, Y., Yung, R. (eds) Geriatric Rheumatology. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-5792-4_4
Download citation
DOI: https://doi.org/10.1007/978-1-4419-5792-4_4
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-5791-7
Online ISBN: 978-1-4419-5792-4
eBook Packages: MedicineMedicine (R0)